Combined chemotherapeutic agent for transplantation pretreatment of thalassemia stem cells in children

Abstract

The invention discloses a combined chemotherapeutic agent for transplantation pretreatment of thalassemia stem cells in children, which comprises the following components: 5 mg / m<2>*5 days of cladrobin, 1.8 g / m<2>*2 days of cyclophosphamide, 4-4.8 mg / kg*3 days of busulfan and 2.5 mg / kg*2 days of anti-human thymus globulin. The combined chemotherapeutic agent is based on the cladrobin, and the cladrobin is combined with the cyclophosphamide, the busulfan and anti-human thymus globulin to perform pre-treatment large-dose chemotherapy before transplantation of Mediterranean stem cells of children, so that the compliance and tolerance of the chemotherapy are improved, the immunosuppression strength is increased, the transplantation success rate of transplantation of stem cells of a patient isimproved, the transplantation-related complications are reduced, the transplantation curative effect is improved, the survival time of the patient is prolonged, and the combined chemotherapeutic agenthas good social benefit and economic benefit and wide clinical application prospect. The efficient and safe pretreatment scheme can be used for transplantation of thalassemia stem cells in children,and the transplantation survival rate is improved.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to pretreatment combined with chemotherapy agents for stem cell transplantation in children with thalassemia. Background technique [0002] Childhood thalassemia is a genetic disease for which hematopoietic stem cell transplantation is the only treatment. Hematopoietic stem cell transplantation is a kind of treatment that destroys the patient's immune system through high-dose radiotherapy and chemotherapy and other immunosuppressant pretreatment, and then transplants allogeneic hematopoietic stem cells to the recipient, so that the patient can rebuild the normal hematopoietic system and achieve a cure for childhood thalassemia. method. The current commonly used cyclophosphamide / fludarabine / busulfan / / anti-thymoglobulin regimen mostly consists of cyclophosphamide 1.8g / m 2 ×2 days, fludarabine 30mg / m 2 × 5 days, busulfan 4-4.8mg / kg × 3 days, antithymoglobulin 2.5mg / kg × 2 days, the...

AI Technical Summary

Problems solved by technology

The current commonly used cyclophosphamide / fludarabine / busulfan / / anti-thymoglobulin regimen mostly consists of cyclophosphamide 1.8g / m 2 ×2 days, fludarabine 30mg / m 2 × 5 days, busulfan 4-4.8mg / kg × 3 days, antithymoglobulin 2.5mg / kg × 2 days, the doses of different centers are slightly different, and the current reported 5-year survival rate is about 85%. Dealing with the toxic side effects of chemotherapy, 10-20% of children still die from transplant-related complications or have severe effects on growth and development

[0003] Cladribine is a compound similar to fudarabine in structure, and has better immunosuppressive effect than fludarabine, but there is no report on its specific use in children with thalassemia transplantation

Images